Relevant events during the quarter
Q1 was a quarter focused on the NEX-22 Ph 1 trial startup. The clinical trial application (CTA) for that study was submitted in Dec'23 but on 16 April Nanexa announced that the start of the study will be delayed towards the end of Q2'24. The main reason for the delay was the request of certain supplements and clarifications by the German Medicines Agency, requiring a new submission of the CTA. Following the resubmission, Nanexa received additional questions, which will be addressed thoroughly. Nanexa's management is confident about solving the issues and expects clinical data from the study by YE'24.
Aktuellt
SENASTE
